NCT01918566

Brief Summary

Our objective is to investigate neuro-anatomical correlates of the regulation of energy intake by means of functional MRI. Administration of glucose with and without lactisole and exendin as well as fructose is followed by functional brain MRI, and findings are correlated with serum GLP-1 levels as an endogenous satiety signal in humans.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
12

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Mar 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2012

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2013

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

May 8, 2013

Completed
3 months until next milestone

First Posted

Study publicly available on registry

August 7, 2013

Completed
Last Updated

August 7, 2013

Status Verified

August 1, 2013

Enrollment Period

1 year

First QC Date

May 8, 2013

Last Update Submit

August 5, 2013

Conditions

Outcome Measures

Primary Outcomes (1)

  • Functional magnetic resonance imaging (fMRI) in healthy volunteers while they performed a working memory task: changes in cerebral blood flow and blood hormones from baseline to treatment

    Whole brain analysis with a cluster-level threshold was followed by an a priori defined region of interest analysis of the dorsolateral prefrontal cortex including a cluster-level threshold and family-wise error adjustment for multiple comparisons.

    changes from baseline to one hour after treatment

Study Arms (6)

300ml tap water

PLACEBO COMPARATOR

Single intragastric instillation of 300ml tap water via nasogastric tube

Dietary Supplement: tap water

Glucose

ACTIVE COMPARATOR

Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube

Dietary Supplement: Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube

Glucose plus Lactisole

ACTIVE COMPARATOR

Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole

Dietary Supplement: Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole

Fructose

ACTIVE COMPARATOR

Single intragastric instillation of 25g Fructose in 300ml tap water via nasogastric tube

Dietary Supplement: 25g Fructose in 300ml tap water

Glucose and Exendin

ACTIVE COMPARATOR

Single intragastric instillation of 75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39

Dietary Supplement: 75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39

tap water, lactisole

SHAM COMPARATOR

Single intragastric instillation of 300ml tap water with 450ppm lactisole

Dietary Supplement: 300ml tap water with 450ppm lactisole

Interventions

Eligibility Criteria

Age18 Years - 35 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • right-handed healthy males, no drugs, non-smoking

You may not qualify if:

  • drug abuse, smoker, left-handed, claustrophobia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Hospital

Basel, CH-4031, Switzerland

Location

MeSH Terms

Conditions

Exploratory Behavior

Interventions

GlucoseFructose

Condition Hierarchy (Ancestors)

Behavior

Intervention Hierarchy (Ancestors)

HexosesMonosaccharidesSugarsCarbohydratesKetoses

Study Officials

  • Christoph Beglinger, MD

    University Hospital, Basel, Switzerland

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
PREVENTION
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 8, 2013

First Posted

August 7, 2013

Study Start

March 1, 2012

Primary Completion

March 1, 2013

Study Completion

March 1, 2013

Last Updated

August 7, 2013

Record last verified: 2013-08

Locations